While the approval of a dengue vaccine is a notable development, some experts warn that it should not be viewed as a silver bullet. There is a significant risk that the focus on vaccination might lead to complacency regarding fundamental public health measures, such as sanitation and urban planning. If the public and policymakers begin to rely solely on the vaccine, the essential work of eliminating mosquito breeding grounds could lose its necessary funding and political momentum.
Critics also point to the complexities of vaccine efficacy across different age groups and previous exposure histories. Because dengue has four distinct serotypes, the immune response can be unpredictable, and there are concerns about how the vaccine performs in real-world conditions compared to controlled clinical trials. Ensuring that the public understands the limitations of the vaccine is crucial to prevent a false sense of security that could lead to increased exposure to mosquito bites.
There are also logistical and economic hurdles that cannot be ignored. A successful national vaccination program requires a massive, sustained investment in cold-chain infrastructure and public education. If the rollout is uneven or if the cost remains high, it could exacerbate existing health inequalities, where only those with access to private healthcare benefit from the protection. This creates a two-tier system that fails to address the needs of the most vulnerable populations living in informal settlements.
Ultimately, the government must ensure that the vaccine is treated as a supplement to, not a replacement for, environmental management. Without a holistic strategy that includes aggressive vector control and improved water management, the vaccine may only provide a partial solution to a much larger systemic problem. Vigilance is required to ensure that this new tool is used effectively without neglecting the root causes of the disease.